3-(3-hydroxy-4-methoxyphenyl)-7-[(2S,4S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 3-(3-hydroxy-4-methoxyphenyl)-7-[(2S,4S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
• 化学式: C₂₂H₂₂O₁₀
• 分子量: 446.4
• InChiKey: WACBUPFEGWUGPB-BLQBXXAQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof
  申请人：Zhu Quan

  公开号：US20110053872A1

  公开（公告）日：2011-03-03

  The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy.